Toshinari Asakura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toshinari Asakura has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Hiroaki Seino
Department of Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Japan
5 shared publicationsKlaus H. Jensen
International Medical Affairs, Novo Nordisk A/S, Sorgenfri, Denmark
2 shared publicationsMiho Kageyama
Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
2 shared publicationsNoriaki Yohkoh
Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
2 shared publicationsReiko Nakano
Department of Pharmacy, Manda Memorial Hospital, Manda, Japan
2 shared publicationsH Seino
Seino Clinic 6-192-2 Kaisei, Koriyama, 963-8851, Japan
1 shared publication
Latest Publications
- Open Access
- 1 September 2011
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 5 (5) , 1203-1209
Comparison of Clinically Relevant Technical Attributes of Five Insulin Injection Pens
Background: Insulin injection pens are the predominant devices for insulin delivery in Europe and Japan because of their ease of use and convenience. This study compared clinically relevant technical attributes of durable insulin pens that are important to people with diabetes, specifically functions relating to cartridge-fitting, dose-setting, and dose-delivery on NovoPen® 4, ClikStar®, HumaPen Luxura®, Itango®, and Biosulin® Pen. Methods: Frequency components and duration of audible clicks on dose setting and injection were measured using audio equipment when setting and delivering 20 IU of insulin. To assess cartridge-fitting torque, each pen was attached to a torque gauge via the attached needle, and torque was measured with each 180° turn as the cartridge was screwed into the body of the pen. Rotary torque of the dose-setting dial was measured when setting the dose to the maximum dose unit of the pen. Injection force was measured when delivering 20 IU at 5 mm/s in a vertical position and at a tilt of 14.7° from vertical. Results: Audible clicks on dose-setting and dose-delivery were most distinguishable on NovoPen 4, while NovoPen 4 and ClikStar had generally lower cartridge-fitting torque and injection (both vertical and angled) force values. Conclusion: Overall, the results showed that durable insulin pens such as NovoPen 4 have useful features related to assembly, dose-setting, and injection, which may facilitate ease of use for diabetes patients, particularly elderly patients and those with visual and/or manual dexterity impairments.
- 1 September 2011
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 5 (5) , 1203-1209
Open AccessComparison of Clinically Relevant Technical Attributes of Five Insulin Injection Pens
Background: Insulin injection pens are the predominant devices for insulin delivery in Europe and Japan because of their ease of use and convenience. This study compared clinically relevant technical attributes of durable insulin pens that are important to people with diabetes, specifically functions relating to cartridge-fitting, dose-setting, and dose-delivery on NovoPen® 4, ClikStar®, HumaPen Luxura®, Itango®, and Biosulin® Pen. Methods: Frequency components and duration of audible clicks on dose setting and injection were measured using audio equipment when setting and delivering 20 IU of insulin. To assess cartridge-fitting torque, each pen was attached to a torque gauge via the attached needle, and torque was measured with each 180° turn as the cartridge was screwed into the body of the pen. Rotary torque of the dose-setting dial was measured when setting the dose to the maximum dose unit of the pen. Injection force was measured when delivering 20 IU at 5 mm/s in a vertical position and at a tilt of 14.7° from vertical. Results: Audible clicks on dose-setting and dose-delivery were most distinguishable on NovoPen 4, while NovoPen 4 and ClikStar had generally lower cartridge-fitting torque and injection (both vertical and angled) force values. Conclusion: Overall, the results showed that durable insulin pens such as NovoPen 4 have useful features related to assembly, dose-setting, and injection, which may facilitate ease of use for diabetes patients, particularly elderly patients and those with visual and/or manual dexterity impairments.
- 1 October 2009
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 11 (10) , 657-661
A Comparison of the Handling and Accuracy of Syringe and Vial Versus Prefilled Insulin Pen (FlexPen)
Background: To determine the preferable method for self-injecting insulin, we compared the handling, safety, and dose accuracy of a conventional disposable syringe and vial with FlexPen® (Novo Nordisk A/S, Bagsvaerd, Denmark), a prefilled pen. Methods: Insulin therapy-naive healthcare professionals (HCPs) (n = 30), unfamiliar with insulin delivery, injected 10 U of insulin into a sponge pad using either a syringe and vial or the FlexPen, both with 30-gauge 8-mm needles, on day 1. The following day, they used the alternative method. They evaluated the handling of the two methods on device-specific questionnaires and compared overall preference on a third questionnaire. To evaluate dose accuracy, 30 insulin therapy-experienced HCPs and 20 insulin therapy-naive HCPs were asked to deliver 10 U of insulin using each method, and the amount discharged was weighed. Results: FlexPen was rated easier to use and overall more preferable than the syringe and vial by insulin therapy-naive HCPs (P < 0.001). The pen device was more accurate than the syringe and vial when used by experienced HCPs (mean ± SD dose delivered, 9.91 ± 0.11 U vs. 9.82 ± 0.25 U, respectively; P < 0.001) and by insulin therapy-naive HCPs (9.91 ± 0.12 U vs. 9.74 ± 0.85 U; P < 0.001). Conclusions: Insulin therapy-naive HCPs found FlexPen easier to handle and preferable to use compared to a conventional syringe and vial. Both insulin therapy-experienced and -naive HCPs were able to deliver insulin significantly more accurately with the FlexPen than with a syringe and vial (P < 0.001).
- 1 October 2009
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 11 (10) , 657-661
A Comparison of the Handling and Accuracy of Syringe and Vial Versus Prefilled Insulin Pen (FlexPen)
Background: To determine the preferable method for self-injecting insulin, we compared the handling, safety, and dose accuracy of a conventional disposable syringe and vial with FlexPen® (Novo Nordisk A/S, Bagsvaerd, Denmark), a prefilled pen. Methods: Insulin therapy-naive healthcare professionals (HCPs) (n = 30), unfamiliar with insulin delivery, injected 10 U of insulin into a sponge pad using either a syringe and vial or the FlexPen, both with 30-gauge 8-mm needles, on day 1. The following day, they used the alternative method. They evaluated the handling of the two methods on device-specific questionnaires and compared overall preference on a third questionnaire. To evaluate dose accuracy, 30 insulin therapy-experienced HCPs and 20 insulin therapy-naive HCPs were asked to deliver 10 U of insulin using each method, and the amount discharged was weighed. Results: FlexPen was rated easier to use and overall more preferable than the syringe and vial by insulin therapy-naive HCPs (P < 0.001). The pen device was more accurate than the syringe and vial when used by experienced HCPs (mean ± SD dose delivered, 9.91 ± 0.11 U vs. 9.82 ± 0.25 U, respectively; P < 0.001) and by insulin therapy-naive HCPs (9.91 ± 0.12 U vs. 9.74 ± 0.85 U; P < 0.001). Conclusions: Insulin therapy-naive HCPs found FlexPen easier to handle and preferable to use compared to a conventional syringe and vial. Both insulin therapy-experienced and -naive HCPs were able to deliver insulin significantly more accurately with the FlexPen than with a syringe and vial (P < 0.001).
- 26 May 2009
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (9) , 1389-1393
Evaluation of injection force of three insulin delivery pens
(2009). Evaluation of injection force of three insulin delivery pens. Expert Opinion on Pharmacotherapy: Vol. 10, No. 9, pp. 1389-1393. doi: 10.1517/14656560903018929
- 26 May 2009
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (9) , 1389-1393
Evaluation of injection force of three insulin delivery pens
(2009). Evaluation of injection force of three insulin delivery pens. Expert Opinion on Pharmacotherapy: Vol. 10, No. 9, pp. 1389-1393. doi: 10.1517/14656560903018929
- Open Access
- 1 March 2009
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 3 (2) , 312-319
Comparison of Intuitiveness, Ease of Use, and Preference in Two Insulin Pens
The intuitiveness, instruction time, and handling of the Levemir® (insulin detemir) FlexPen® and the Lantus® OptiClik® pen (with insulin glargine) were investigated. This randomized open-label crossover study involved two groups of insulin-device-naive Japanese patients with type 2 diabetes [mean (SD) age 61.9 ± 12.3 years, 57% male]. Patients were evaluated on the ease-of-use of each insulin pen without instruction [intuitiveness group (n = 32)], or with instruction [instruction time group (n = 29)]. Patient preferences for the respective devices were assessed by questionnaire. FlexPen required significantly less instruction time (p < .001) and was objectively more intuitive to use (p < .001) than OptiClik. Nevertheless, few patients in the intuitiveness group felt confident injecting either pen prior to instruction (FlexPen, 31%; OptiClik, 16%). No patients in the instruction time group found FlexPen difficult to learn, whereas 45% of patients found OptiClik difficult or very difficult to learn. FlexPen was rated simpler to use (77% versus 12%; p < .001), easier to inject (67% versus 13%; p < .001), and more convenient (71% versus 12%; p < .001) compared with OptiClik. More patients would trust FlexPen to deliver insulin injections (p < .01) and would prefer to use FlexPen compared with OptiClik (82% versus 13%; p < .001). FlexPen was faster to teach, simpler to use, and more trusted by patients compared with OptiClik. Mean injection time was significantly shorter for FlexPen than OptiClik, with or without instruction. This study highlights not only how easy it is for patients to learn to use FlexPen, but also how easily health care providers can teach patients to use it.
- 1 March 2009
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 3 (2) , 312-319
Open AccessComparison of Intuitiveness, Ease of Use, and Preference in Two Insulin Pens
The intuitiveness, instruction time, and handling of the Levemir® (insulin detemir) FlexPen® and the Lantus® OptiClik® pen (with insulin glargine) were investigated. This randomized open-label crossover study involved two groups of insulin-device-naive Japanese patients with type 2 diabetes [mean (SD) age 61.9 ± 12.3 years, 57% male]. Patients were evaluated on the ease-of-use of each insulin pen without instruction [intuitiveness group (n = 32)], or with instruction [instruction time group (n = 29)]. Patient preferences for the respective devices were assessed by questionnaire. FlexPen required significantly less instruction time (p < .001) and was objectively more intuitive to use (p < .001) than OptiClik. Nevertheless, few patients in the intuitiveness group felt confident injecting either pen prior to instruction (FlexPen, 31%; OptiClik, 16%). No patients in the instruction time group found FlexPen difficult to learn, whereas 45% of patients found OptiClik difficult or very difficult to learn. FlexPen was rated simpler to use (77% versus 12%; p < .001), easier to inject (67% versus 13%; p < .001), and more convenient (71% versus 12%; p < .001) compared with OptiClik. More patients would trust FlexPen to deliver insulin injections (p < .01) and would prefer to use FlexPen compared with OptiClik (82% versus 13%; p < .001). FlexPen was faster to teach, simpler to use, and more trusted by patients compared with OptiClik. Mean injection time was significantly shorter for FlexPen than OptiClik, with or without instruction. This study highlights not only how easy it is for patients to learn to use FlexPen, but also how easily health care providers can teach patients to use it.
- 1 August 2008
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 10 (4) , 299-304
Patient Acceptance and Issues of Education of Two Durable Insulin Pen Devices
Background: Insulin pen devices offer patients a more convenient, accurate, and discreet mode of insulin delivery than traditional syringes and vials. This open-label, randomized, comparative crossover study assessed patient preference for two reusable pens: NovoPen ® 4 (Novo Nordisk A/S, Copenhagen, Denmark) and OptiClik ® (Sanofi-Aventis, Bridgewater NJ). Methods: Thirty-five diabetes patients with no previous experience of pen devices (mean age 56.7 years; range 17–80 years; 57% male) used both pens to deliver a 10 unit saline dose into an injection cushion. Half received guidance according to official instruction manuals, and half were given no instructions. Learning times were also measured. Participants completed a detailed questionnaire to determine their preferences. Results: Overall, 32 of 35 participants preferred NovoPen 4 compared with two of 35 for OptiClik (91.4% vs. 5.7% respectively, P < 0.001), and one had no preference. NovoPen 4 was significantly favored over OptiClik in almost all questionnaire criteria, including safety ( P < 0.001), size of pen ( P < 0.001), appearance ( P < 0.001), and ease of use ( P < 0.001). The majority of patients were able to use NovoPen 4 without guidance (94.4%) compared with just over half for for OptiClik (55.6%, P < 0.01). Learning time was also significantly faster for NovoPen 4 (62.6 s) than for OptiClik (95.8 s) ( P < 0.05). Conclusions: Patients learned how to use both pens quickly (under 2 min), but NovoPen 4 was preferred by participants over OptiClik. Patient acceptance of a pen device may support insulin initiation, particularly in type 2 diabetes.
- 1 August 2008
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 10 (4) , 299-304
Patient Acceptance and Issues of Education of Two Durable Insulin Pen Devices
Background: Insulin pen devices offer patients a more convenient, accurate, and discreet mode of insulin delivery than traditional syringes and vials. This open-label, randomized, comparative crossover study assessed patient preference for two reusable pens: NovoPen ® 4 (Novo Nordisk A/S, Copenhagen, Denmark) and OptiClik ® (Sanofi-Aventis, Bridgewater NJ). Methods: Thirty-five diabetes patients with no previous experience of pen devices (mean age 56.7 years; range 17–80 years; 57% male) used both pens to deliver a 10 unit saline dose into an injection cushion. Half received guidance according to official instruction manuals, and half were given no instructions. Learning times were also measured. Participants completed a detailed questionnaire to determine their preferences. Results: Overall, 32 of 35 participants preferred NovoPen 4 compared with two of 35 for OptiClik (91.4% vs. 5.7% respectively, P < 0.001), and one had no preference. NovoPen 4 was significantly favored over OptiClik in almost all questionnaire criteria, including safety ( P < 0.001), size of pen ( P < 0.001), appearance ( P < 0.001), and ease of use ( P < 0.001). The majority of patients were able to use NovoPen 4 without guidance (94.4%) compared with just over half for for OptiClik (55.6%, P < 0.01). Learning time was also significantly faster for NovoPen 4 (62.6 s) than for OptiClik (95.8 s) ( P < 0.05). Conclusions: Patients learned how to use both pens quickly (under 2 min), but NovoPen 4 was preferred by participants over OptiClik. Patient acceptance of a pen device may support insulin initiation, particularly in type 2 diabetes.
- 8 April 2008
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (5) , 1429-1434
Dosing accuracy of two insulin pre-filled pens
Objective: This study was designed to determine the dose accuracy of two commonly available insulin pre-filled pens for use in diabetes – FlexPen (Novo Nordisk A/S, Bagsværd, Denmark) (FP) and SoloStar (Sanofi-Aventis, Paris, France) (SS).Research design and methods: Dosing accuracy was tested at 5 U, 10 U and 30 U doses – three previously unused pens of both pre-filled pens were used for each dose. At the 5 U dose each pen was tested 42 times, at the 10 U dose each pen was tested 25 times and at the 30 U dose each pen was tested 9 times. The pre-filled pens were used strictly according to manufacturers’ instructions and measurements were made on a sensitive balance and corrected for the specific density of the insulin formulations used. Specified limits were based on ISO standards (±1 U for the 5 U and 10 U doses and ±1.5 U for the 30 U dose).Results: FP was more accurate for injecting 5 U, 10 U and 30 U doses (absolute mean 4.95 ± 0.19 U, 9.61 ± 0.27 U and 29.70 ± 0.34 U, respectively) than SS (...
- 8 April 2008
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (5) , 1429-1434
Dosing accuracy of two insulin pre-filled pens
Objective: This study was designed to determine the dose accuracy of two commonly available insulin pre-filled pens for use in diabetes – FlexPen (Novo Nordisk A/S, Bagsværd, Denmark) (FP) and SoloStar (Sanofi-Aventis, Paris, France) (SS).Research design and methods: Dosing accuracy was tested at 5 U, 10 U and 30 U doses – three previously unused pens of both pre-filled pens were used for each dose. At the 5 U dose each pen was tested 42 times, at the 10 U dose each pen was tested 25 times and at the 30 U dose each pen was tested 9 times. The pre-filled pens were used strictly according to manufacturers’ instructions and measurements were made on a sensitive balance and corrected for the specific density of the insulin formulations used. Specified limits were based on ISO standards (±1 U for the 5 U and 10 U doses and ±1.5 U for the 30 U dose).Results: FP was more accurate for injecting 5 U, 10 U and 30 U doses (absolute mean 4.95 ± 0.19 U, 9.61 ± 0.27 U and 29.70 ± 0.34 U, respectively) than SS (...
- 1 August 2006
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 8 (4) , 489-494
Usability of a Microtapered Needle (TN3305) for Insulin Treatment in Japanese Patients with Diabetes Mellitus: A Comparative Clinical Study with a Standard Thin Wall Needle
Background: We evaluated the clinical usability of a microtapered needle (TN3305, "Needle T," Terumo Corp., Tokyo, Japan) by comparing it with a standard needle (Micro-Fine™ +, 31 gauge, 5 mm, thin wall, "Needle B," Nippon Becton Dickinson Co., Ltd., Tokyo) in a multicenter study. Methods: Ninety-nine patients with diabetes mellitus being treated in 11 Japanese hospitals were enrolled in the study. Written consent was obtained from all patients. They were allocated randomly to two groups by an envelope (crossover) method. Injections were performed using one needle first, followed by the other needle 4 or 5 days later. Pain caused by injection was evaluated using a visual analogue scale (VAS). Results: In the overall evaluation, Needle T was chosen by 40 patients (44.4%) and Needle B by 17 (18.8%); 33 patients (36.7%) expressed no preference. VAS scores for Needles T and B were 1.48 ± 0.18 and 2.47 ± 0.24 cm, respectively (P < 0.001). In this study, lower VAS indicated less pain. Conclusions: The preferences and VAS scores suggested that Needle T caused less pain than Needle B. The incidence of adverse events and safety were equivalent for both needles. We believe that usability of Needle T by patients for self-injection is better.
- 1 August 2006
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 8 (4) , 489-494
Usability of a Microtapered Needle (TN3305) for Insulin Treatment in Japanese Patients with Diabetes Mellitus: A Comparative Clinical Study with a Standard Thin Wall Needle
Background: We evaluated the clinical usability of a microtapered needle (TN3305, "Needle T," Terumo Corp., Tokyo, Japan) by comparing it with a standard needle (Micro-Fine™ +, 31 gauge, 5 mm, thin wall, "Needle B," Nippon Becton Dickinson Co., Ltd., Tokyo) in a multicenter study. Methods: Ninety-nine patients with diabetes mellitus being treated in 11 Japanese hospitals were enrolled in the study. Written consent was obtained from all patients. They were allocated randomly to two groups by an envelope (crossover) method. Injections were performed using one needle first, followed by the other needle 4 or 5 days later. Pain caused by injection was evaluated using a visual analogue scale (VAS). Results: In the overall evaluation, Needle T was chosen by 40 patients (44.4%) and Needle B by 17 (18.8%); 33 patients (36.7%) expressed no preference. VAS scores for Needles T and B were 1.48 ± 0.18 and 2.47 ± 0.24 cm, respectively (P < 0.001). In this study, lower VAS indicated less pain. Conclusions: The preferences and VAS scores suggested that Needle T caused less pain than Needle B. The incidence of adverse events and safety were equivalent for both needles. We believe that usability of Needle T by patients for self-injection is better.
- 1 August 2005
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 7 (4) , 620-626
Assessment of Dose Selection Attributes with Audible Notification in Insulin Pen Devices
Background: Patients with type 2 diabetes often suffer from impairments in vision as well as manual dexterity. The purpose of this study was to assess the reliability of dose selection and setting of five insulin devices by patients using auditory and sensory confirmation. Methods: A total of 48 patients (30 men, 18 women; mean ± SD age 60.5 ± 14.0 years; hemoglobin A1c 8.7 ± 1.9%) were randomized to test the following devices: NovoPen® 3 (Novo Nordisk A/S, Bagsvaerd, Denmark), HumaPen® Ergo (Eli Lilly, Indianapolis, IN), Humalog® Pen (Eli Lilly), InnoLet® (Novo Nordisk), and FlexPen® (Novo Nordisk). Results: Significantly more patients detected an auditory confirmation of dose setting when using the NovoPen 3 compared with the Humalog Pen (P < 0.001), HumaPen Ergo (P < 0.001), and InnoLet (P < 0.01). The audible click for the FlexPen was also heard by more patients than for the Humalog Pen (P < 0.001) and HumaPen Ergo (P < 0.01). All patients found that the Flex- Pen provided physical sensory confirmation; the percentage was higher than for those using the Humalog Pen (P < 0.001), HumaPen Ergo (P < 0.001), and InnoLet (P < 0.01). The NovoPen 3 was also associated with a higher percentage of patients who felt the click sensation than with the Humalog Pen (P < 0.001) and HumaPen Ergo (P < 0.01). Patients reported more confidence in setting the correct dose with the NovoPen 3 and FlexPen, and found these the most reliable for dose setting. Sound recordings showed that the NovoPen 3 produced the loudest clicks when setting a dose (P < 0.001 for all comparisons). Conclusions: The clarity of the click when setting a dose on an insulin delivery device can affect the patient's confidence in selecting the correct dose.
- 1 August 2005
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 7 (4) , 620-626
Assessment of Dose Selection Attributes with Audible Notification in Insulin Pen Devices
Background: Patients with type 2 diabetes often suffer from impairments in vision as well as manual dexterity. The purpose of this study was to assess the reliability of dose selection and setting of five insulin devices by patients using auditory and sensory confirmation. Methods: A total of 48 patients (30 men, 18 women; mean ± SD age 60.5 ± 14.0 years; hemoglobin A1c 8.7 ± 1.9%) were randomized to test the following devices: NovoPen® 3 (Novo Nordisk A/S, Bagsvaerd, Denmark), HumaPen® Ergo (Eli Lilly, Indianapolis, IN), Humalog® Pen (Eli Lilly), InnoLet® (Novo Nordisk), and FlexPen® (Novo Nordisk). Results: Significantly more patients detected an auditory confirmation of dose setting when using the NovoPen 3 compared with the Humalog Pen (P < 0.001), HumaPen Ergo (P < 0.001), and InnoLet (P < 0.01). The audible click for the FlexPen was also heard by more patients than for the Humalog Pen (P < 0.001) and HumaPen Ergo (P < 0.01). All patients found that the Flex- Pen provided physical sensory confirmation; the percentage was higher than for those using the Humalog Pen (P < 0.001), HumaPen Ergo (P < 0.001), and InnoLet (P < 0.01). The NovoPen 3 was also associated with a higher percentage of patients who felt the click sensation than with the Humalog Pen (P < 0.001) and HumaPen Ergo (P < 0.01). Patients reported more confidence in setting the correct dose with the NovoPen 3 and FlexPen, and found these the most reliable for dose setting. Sound recordings showed that the NovoPen 3 produced the loudest clicks when setting a dose (P < 0.001 for all comparisons). Conclusions: The clarity of the click when setting a dose on an insulin delivery device can affect the patient's confidence in selecting the correct dose.